Provided by Tiger Trade Technology Pte. Ltd.

Tempest Therapeutics Inc.

0.8112
+0.00510.63%
Post-market: 0.8000-0.0112-1.38%19:59 EDT
Volume:2.27M
Turnover:1.86M
Market Cap:13.70M
PE:-0.18
High:0.8500
Open:0.8239
Low:0.7800
Close:0.8061
52wk High:12.23
52wk Low:0.7432
Shares:16.89M
Float Shares:9.60M
Volume Ratio:10.14
T/O Rate:23.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.5617
EPS(LYR):-19.4955
ROE:-931.14%
ROA:-79.37%
PB:-12.57
PE(LYR):-0.04

Loading ...

Tempest Therapeutics Names Nancy Freda-Smith to Board

Reuters
·
13 hours ago

Tempest Therapeutics Appoints Nancy Freda-Smith to Board, Names Her Audit Committee Chair

Reuters
·
Sep 29

Tempest Therapeutics - Prospectus Filed for Offer and Resale of up to 9,534,164 Shares of Common Stock - SEC Filing

THOMSON REUTERS
·
Sep 26

Tempest Therapeutics Inc : H.c. Wainwright Cuts Target Price to $7 from $11

THOMSON REUTERS
·
Sep 24

Tempest Therapeutics Appoints Nancy Freda-Smith to Board, Names Her Audit Committee Chair

Reuters
·
Sep 23

Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors

THOMSON REUTERS
·
Sep 23

Tempest Therapeutics Signs Exclusive Option Deal with Senlang for CD7-Targeted in Vivo CAR-T Platform

Reuters
·
Sep 18

Tempest Therapeutics Special Meeting Adjourned After Proposal Fell Short of 75% Vote Threshold

Reuters
·
Sep 17

Top Premarket Gainers

MT Newswires Live
·
Sep 16

Tempest Therapeutics Gains Option to License New In-Body CAR-T Technology From Senlang

MT Newswires Live
·
Sep 16

Tempest Secures Exclusive Option to License Clinical-Stage Cd7-Targeted Lentiviral in Vivo CAR-T Platform

THOMSON REUTERS
·
Sep 16

Tempest Therapeutics Inc: Entered into an Exclusive Option Agreement with Hebei Senlang Biotechnology Co., Ltd

THOMSON REUTERS
·
Sep 16

Tempest Therapeutics - no Grade 3 or Higher Cytokine Release Syndrome or Neurotoxicity as of Aug 25, 2026

THOMSON REUTERS
·
Sep 16

Tempest Therapeutics announces $7.5M private placement

TIPRANKS
·
Sep 11

Tempest Therapeutics Prices $2.5 Million Private Placement at $0.81 Per Share

Reuters
·
Sep 11

Tempest Therapeutics Announces up to $7.5 Million Private Placement

THOMSON REUTERS
·
Sep 11

Tempest Therapeutics CEO to Present at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 08

Tempest Therapeutics - Justin Trojanowski to Resign as Principal Financial Officer and Principal Accounting Officer Effective Sept 1 - SEC Filing

THOMSON REUTERS
·
Aug 25

Tempest Therapeutics - Appoints Nicholas Rossettos as CFO, Principal Financial and Accounting Officer Effective Sept 1, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 25

Tempest Therapeutics Names Nicholas Rossettos CFO, Replacing Justin Trojanowski

Reuters
·
Aug 25